Melatonin enhances everolimus efficacy in breast cancer by suppressing mTOR pathway activation and promoting apoptosis and mitochondrial function
Abstract Background Everolimus is used in the treatment of breast cancer by targeting the PI3K/AKT/mTOR pathway, particularly during anti-hormonal therapy. The efficacy of everolimus is limited due to a feedback loop that supresses mTOR while simultaneously enhancing Akt activation in endocrine-resi...
Saved in:
| Main Authors: | Şeyma Demirkesen, Yakup İriağaç, Erdoğan Selçuk Şeber, Cenk Aral |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | BMC Pharmacology and Toxicology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40360-025-00907-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A case of sternal osteomyelitis during treatment with everolimus for recurrent breast cancer
by: Kaori Abe, et al.
Published: (2022-01-01) -
TSC2-mutated perivascular epithelioid cell tumor with partial response to mTOR inhibition: a case report and literature review
by: Xiaopeng Suo, et al.
Published: (2025-07-01) -
The Role of mTOR in <i>Mycobacterium tuberculosis</i> Infection
by: Ami Patel, et al.
Published: (2024-10-01) -
Defects in GABA metabolism affect selective autophagy pathways and are alleviated by mTOR inhibition
by: Ronak Lakhani, et al.
Published: (2014-02-01) -
Rapamycin for longevity: the pros, the cons, and future perspectives
by: Kelley M. Roark, et al.
Published: (2025-06-01)